MicroRNA profiling in early hypertrophic growth of the left ventricle in rats

https://doi.org/10.1016/j.bbrc.2010.05.039Get rights and content

Abstract

Pressure overload induces hypertrophic growth of the heart and in the long term this condition can lead to cardiomyopathy and heart failure. Several miRNAs are upregulated in heart failure. However, it is not clear, which miRNAs (if any) are induced during the early hypertrophic growth phase.

To investigate whether the upregulation of miRNAs is an integrated part of hypertrophic growth or an effect of cardiac disease we investigated miRNA expression in early hypertrophic development. Hypertrophy was induced by banding of the ascending aorta of male rats. After 14 days, the heart left ventricle weight relative to body weight of animals with aortic banding had increased 65% compared to matched control rats. Furthermore, RNA was extracted from left ventricles and reverse transcription qPCR showed that expression of the hypertrophic markers atrial natriuretic peptide and brain natriuretic peptide was highly induced in animals with aortic banding.

Out of 13 miRs that have previously been reported to be associated with late-stage pressure-overload-induced hypertrophy and heart failure only four (miR-23a, miR-27b, miR-125b and miR-195) were induced during early hypertrophic growth. These miRs were previously associated with angiogenesis and cell growth and their expression in early hypertrophic growth was accompanied by a twofold upregulation of the cell-cycle regulator cyclin D2 that is a marker of cardiac growth.

Our results indicate that different miRNAs are involved in early hypertrophic growth than in late stage pressure-overload induced heart failure.

Introduction

Precise regulation of gene expression is vital for the normal development of living organisms. Gene regulation is achieved by multiple mechanisms operating at transcriptional, post-transcriptional and post-translational levels. The discovery of microRNAs by Ambros and coworkers [1] radically changed our understanding of gene regulation in eukaryotes. MicroRNAs (miRNAs) are highly conserved 21–23 nucleotides long non-coding RNAs that regulate gene expression at the post-transcriptional level. By annealing to partially complementary sequences in the target messenger RNAs, the microRNAs mostly mediate translational repression or degradation of the mRNAs, resulting in down-regulation of the protein level. However, miRNA are also able to stimulate gene expression [2]. More than 700 microRNAs have been identified in the human genome (miRBase release 14.0). Many studies concerning functional characterization of known microRNAs in different physiological scenarios have been published in the last years. The majority of microRNAs seem to act cooperatively with many target sites in one gene and they can also target several genes, which add high complexity to the gene regulatory networks [3]. MicroRNAs are important regulators of many biological processes, including development, differentiation and apoptosis [4]. Consequently aberrant expression of microRNAs has been associated with disease. For example, several miRNAs behave as oncogenes or tumour suppressor genes in many types of cancer (reviewed by [5]).

Cardiac hypertrophy or thickening of the heart muscle occurs in response to increased blood pressure that preserves myocardial wall stress, chamber size and contractile function. Cardiac hypertrophy, which is a risk factor for cardiovascular disease, can be induced by a number of stimuli, like long-term exposure to pressure-overload, and if untreated it can lead to cardiomyopathy (defined as weakness of the individual muscle fibres of the heart) and heart failure [6].

MicroRNAs are highly expressed in the heart and they have important regulatory roles during cardiomyocyte differentiation, cell cycle and during cardiac hypertrophy [4], [7]. In particular miR-133 and miR-1 are specifically expressed in cardiac and skeletal muscle and play important roles in muscle cell proliferation and differentiation [8]. However, in rats, hypertrophic growth of the left ventricle defined as weight gain relative to body weight ceases within 4 weeks of aortic banding [16] and miRNA expression in the heart has mainly been investigated after this time. It was therefore of interest to investigate whether the miRNAs expressed in late stage hypertrophy and heart failure are also involved in early hypertrophic growth.

Section snippets

Aortic Banding

Male Wistar rats weighing 70–90 g from Møllegaard Breeding Center (Lille Skensved, Denmark) were kept at Rigshospitalet with a 12:12-h light–dark cycle, and fed standard rat chow. During Hypnorm/Dormicum (0.2 ml/100 g sc; Boehringer Ingelheim, Ingelheim, Germany) and 1–1.5% isoflurane (Abbott Laboratories, Abbott Park, IL) anesthesia the ascending aorta was exposed by left-side thoracotomy, and a titanium clip with an inner diameter of 0.6 mm was placed 5 mm above the aortic valves with a

Physiological results

In animals with aortic banding, the left ventricle weight (LVW) relative to body weight (BW) increased 65% compared to the sham group after 14 days (P < 0.001) whereas there was no difference (P = 0.325) in the body weight of the two groups (Fig. 1, Table 1). The result indicates that there was hypertrophic growth of the left ventricle in the animals with aortic banding.

Expression of hypertrophic markers

The growth of the left ventricle was accompanied by upregulation of mRNA for the hypertrophic markers atrial natriuretic peptide

Discussion

In the present study, we used a rat model for pressure overload-induced hypertrophy that was previously established in our lab [10], [12], [16]. In agreement with our previous reports, the weight of the left ventricle of animals with aortic constriction was significantly higher than in sham-operated animals. This is in accordance with that the animals with aortic constriction develop pressure overload-induced left ventricle hypertrophy [16]. Furthermore, expression analysis showed that the mRNA

Role of the funding sources

None of the supporting sources had any role in study design; in the collection, analysis, and interpretation of data; in the writing of the report and in the decision to submit the paper for publication.

Acknowledgments

We thank Pernille Gundelach and Minna Jakobsen for excellent technical help, Tue E.H. Christoffersen for discussions on animal experiments and Frederikke Egerod for storage of samples.

This work was supported by grants from the Danish Heart Association, the Danish Medical Research Council, the Birthe and John Meyer Foundation, Villadsen Family Foundation, Kong Christian X’s Foundation, the Illum Foundation and Fru Asta Florida Bolding Foundation.

References (39)

  • S. Vasudevan et al.

    Switching from repression to activation: microRNAs can up-regulate translation

    Science

    (2007)
  • K.R. Cordes et al.

    MicroRNA regulation of cardiovascular development

    Circ. Res.

    (2009)
  • R. Garzon et al.

    MicroRNAs in Cancer

    Annu. Rev. Med.

    (2009)
  • K.R. Chien et al.

    Molecular biology of cardiac hypertrophy and heart failure

  • T. Thum et al.

    MicroRNAs: novel regulators in cardiac development and disease

    Cardiovasc. Res.

    (2008)
  • T.E. Christoffersen et al.

    Increased natriuretic peptide receptor A and C gene expression in rats with pressure-overload cardiac hypertrophy

    Am. J. Physiol. Heart Circ. Physiol.

    (2006)
  • M.W. Pfaffl et al.

    Relative expression software tool (REST) for group-wise comparison andstatistical analysis of relative expression results in real-time PCR

    Nucleic Acids Res.

    (2002)
  • P.K. Busk et al.

    Involvement of cyclin D activity in left ventricle hypertrophy in vivo and in vitro

    Cardiovasc. Res.

    (2002)
  • A. Carè et al.

    MicroRNA-133 controls cardiac hypertrophy

    Nat. Med.

    (2007)
  • Cited by (46)

    • Methamphetamine produces cardiac damage and apoptosis by decreasing melusin

      2019, Toxicology and Applied Pharmacology
      Citation Excerpt :

      The reason may be that melusin causes physiological hypertrophy, while METH causes pathological hypertrophy, which operates according to different mechanisms and pathways. To date, many factors have been reported to cause cardiac hypertrophy, and different stimuli cause cardiac hypertrophy by activating different signal sensors and signaling pathways; for example, catecholamines or angiotensin II can activate Ca2+ channels or the JAK-STAT signaling pathway, while the NF-κB signaling pathway and some miRNAs can cause cardiac hypertrophy (Ling et al., 2009; Kehat and Molkentin, 2010; Rohini et al., 2010; Freund et al., 2005; Callis et al., 2009; Rane et al., 2009; Busk and Cirera, 2010). Therefore, in order to determine whether the early presence of melusin is involved in METH-induced cardiac hypertrophy, the specific mechanism remains to be further explored, which may be related to the timing, the dose and even the purity of METH (Akhgari et al., 2017; Maeno et al., 2000).

    • miR-125b is a protectomiR: A rising star for acute cardioprotection

      2018, Journal of Molecular and Cellular Cardiology
    • MicroRNAs in heart failure: Non-coding regulators of metabolic function

      2016, Biochimica et Biophysica Acta - Molecular Basis of Disease
      Citation Excerpt :

      Furthermore, both miR-9 and miR-146 have been shown to inhibit SIRT1, and therefore repress SIRT1-mediated deacetylation, leading to attenuated insulin secretion [112–114]. Interestingly, miR-195, which is upregulated in early and late stage hypertrophy and HF, has also been shown to directly bind to the 3’UTR of SIRT1 and inhibit its expression in cardiomyocytes [21,115,116]. While miRNA-mediated SIRT1 regulation is well known, the regulation of other SIRT family members by miRNAs has just begun to be explored (Table 3).

    View all citing articles on Scopus
    View full text